GLP-1 receptor agonists have rapidly become a cornerstone of obesity and metabolic disease management, with widespread adoption across primary care, endocrinology, and specialized weight management practices. As utilization increases, clinicians are encountering a broader spectrum of comorbid gastrointestinal conditions, among which Helicobacter pylori (H. pylori) infection remains highly prevalent. This raises an important and increasingly
